This month we provide you with a deal analysis overview of life science partnering, M&A and financing in July 2014.
Welcome to the August 2014 edition of Current Agreements Deals Update.
This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in July 2014.
Deal of the month
Asset purchase agreement for specialty and branded generic business
Jul 17 2014 - Abbott Laboratories, Mylan Laboratories
Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business in an all-stock transaction.The transaction will instantly further diversify Mylan's business and strengthen its commercial platform outside......more
Breaking news...
Acquisition agreement for Rottapharm-Madaus
Jul 31, 2014 - Meda, Rottapharm-Madaus
Meda announced today that it has entered into a definitive agreement to acquire Rottapharm-Madaus; an Italian company owned by the Rovati family, for a consideration of SEK 21.2 billion on a cash and debt free basis......more
For more breaking deals as they are announced, visit:http://www.currentagreements.com
July 2014 has been yet another busy month with the announcements of many high value deals bringing the total number of deals for the month to 258. The top partnering deal by value was the asset purchase agreement for the specialty and branded generics business between Abbott Laboratories and Mylan Laboratories worth $USD 5.3bn. Further details can be viewed here.
On the M&A front, 43 deals were announced; the leading deal was the acquisition of Rottapharm-Madaus by Meda in a deal valued at $USD 3.08bn. Further details can be viewed here.
On the financings front we recorded 116 announcements, with the leading deal by value being the equity repurchase for $5bn by Johnson & Johnson. Further details can beviewed here.
Our sister company, Current Partnering published several new and updated reports:
- Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics
- Personalized Medicine in Oncology Partnering Terms and Agreements
- Trends in Therapeutic Partnering
View our full list of reports here at our report store.
Our Current Partnering website showcases the leading partnering, M&A and financing deals by value.
To see all of 2014 leading deals and view the full set of Scorecards for 2014, visit Partnering scorecard | M&A scorecard | Financing scorecard - check them out.
We welcome your comments and feedback on this newsletter. We are also interested in hearing from any company with a deal not announced by press release; this allows us to add further non-publicized deals to the database.
Best regards,
Shamini Thiagarajan
Top ten deal analysis of the month by deal value
The following are the top 10 partnering deals and alliances by value, as announced in July 2014.
1. Asset purchase agreement for specialty and branded generics business - Abbott Laboratories, Mylan Laboratories - $5.3bn
2. Asset purchase and licensing agreement for respiratory business and its pipeline- Almirall, AstraZeneca- $2.1bn
3. Contract service agreement for developing Technical Area Tasks- American International Biotechnology Services, Department of Defense, Leidos Holdings- $900m
4. Grant award for $650 million for psychiatric disorder- Broad Institute - $650m
5. Asset purchase agreement for vaccine business - Baxter International, Pfizer- $635m
6. Licensing and collaborative R&D agreement for novel peptide medicines - Boehringer Ingelheim, Zealand Pharma - $402m
7. Asset purchase agreement for LTS Lohmann - BWK, LTS Lohmann Therapie-Systeme, Novartis, dievini Hopp BioTech - $400m
8. Joint venture agreement for dairy farms - Abbott Laboratories, Fonterra - $300m
9. Asset purchase agreement for Defibrotide - Jazz Pharmaceuticals, Sigma-Tau- $250m
10. Grant award for $248 million for electroceuticals project - National Institutes of Health, Simons Foundation - $248m
Full details of each deal available at Current Agreements*
*Subscription required
Big pharma deal analysis July 2014
July saw 41 partnering deals announced with big pharma being at least one of the parties of the deal.
Pfizer were particularly active, leading partnering activities in July.
Pfizer partnering- July 2014
- Asset purchase agreement for small stake in Cellectis - with Cellectis
- Asset purchase agreement for vaccine business -with Baxter International
- Licensing agreement for BCRP-MDCK cells -with Absorption Systems
- Collaboration agreement for drug for epilepsy -with Epilepsy Foundation (EF), Intellimedix
- Development agreement for population health management - with CliniWorks
Pfizer partnering interests
Pfizer partnering report
Further details of all big pharma deals are available at Current Agreements.
Big biotech deal analysis July 2014
July saw 11 partnering deals announced with big biotech being at least one of the parties of the deal.
Roche with its subsidiary Genentech were particularly active, leading partnering activity in July.
Roche partnering- July 2014
- Collaboration agreement to evaluate efficacy of INCB24360 in combination with MPDL3280A -with Incyte
- Collaboration and option agreement for small molecule discovery - with AmorChem
- Collaboration agreement for development of companion diagnostic for AZD9291 -with AstraZeneca
Roche partnering report
Further details of all big pharma deals are available at Current Agreements.
Current Agreements products
CP Knowledge Centre : Access the best of Current Partnering and Current Agreements with a CP Knowledge Center subscription. Buy now
